Detection of GB virus C genomic sequence in the cerebrospinal fluid of a HIV-infected patient in China: a case report and literature review

Z. LIU1†, Y. ZHANG1†, F. WEI2, M. XU1, D. MOU1, T. ZHANG1, W. LI1, D. CHEN2* and H. WU1*

1 STD/AIDS Research Center, Beijing Key Laboratory, Beijing You An Hospital, Capital Medical University, Beijing, China
2 Beijing Institute of Hepatology, Beijing, China

Received 25 November 2014; Final revision 17 April 2015; Accepted 30 May 2015; first published online 17 June 2015

SUMMARY

Hepatitis G virus or GB virus C (GBV-C) is a human virus of the Flaviviridae family that is structurally and epidemiologically closest to hepatitis C virus, but replicates primarily in lymphocytes. Co-infection with GBV-C has been reported to confer beneficial outcomes in some HIV-positive patients. Up to now, however, studies on GBV-C infection in the central nervous system (CNS) of HIV-infected patient have rarely been reported. Herein, we report on a 32-year-old HIV-1-infected patient with cerebral toxoplasmosis and fungal encephalitis. GBV-C viral loads were detected in CSF by quantitative real-time reverse transcription polymerase chain reaction (RT–PCR), and the results showed that GBV-C viral load was 6·5 log copies/ml. We amplified and sequenced the E2 and 5'-untranslated regions from the purified viral RNA from CSF by RT–PCR. Both sequences belong to genotype 3 and there were some minor nucleotide divergence among the E2 sequences from the CSF of the patient. These data suggest that GBV-C may be able to penetrate the blood–brain barrier and colonize the CNS of HIV-infected patients. However, the exact mechanisms and potential effect of the infected GBV-C in CNS on HIV-associated neuropathy needs to be further explored.

Key words: Cerebrospinal fluid (CSF), encephalitis, GB virus C, human immunodeficiency virus type 1.

INTRODUCTION

GBV-C is a human virus of the Flaviviridae family that is structurally and epidemiologically closest to hepatitis C virus (HCV). Commonly, only 1–4% of healthy blood donors have GBV-C viraemia at the time of blood donation in the USA [1, 2]. A high prevalence (up to 50%) of active (GBV-C viraemia) or prior (emergence of anti-E2) GBV-C infection is observed in HIV-infected patients since similar transmission [3–5]. GBV-C replicates primarily in T and B lymphocytes and in peripheral blood mononuclear cells [6, 7], and poorly, if at all, in hepatocytes [8–10]. Transmission routes of GBV-C through parental and sexual contact [11, 12], and vertically from mother to child have been documented, and GBV-C infection is common in many populations [5, 13]. Although GBV-C is initially thought to be associated with chronic hepatitis, extensive investigation has failed to identify any association between this virus and any clinical illness. In contrast with HCV, a
number of studies have reported HIV-positive patients co-infected with GBV-C to achieve beneficial outcomes [13–15]. However, some contradictory reports regarding the effects of GBV-C on the course of HIV infection are present [16, 17].

The effect of GBV-C/HIV-1 co-infection on the progress of HIV-infected disease is still not well known. Some evidence has demonstrated the molecular interactions between these two viruses [18–20]. GBV-C is commonly detected in the blood of HIV-infected patients; up to now, however, studies on GBV-C infection in the central nervous system (CNS) of HIV-infected patients have rarely been reported. In this paper, we report on a HIV-1-infected patient with detectable GBV-C viraemia in the cerebrospinal fluid (CSF). However, the neuropathological effect of GBV-C viraemia in CSF on HIV-infected patients needs to be further explored.

CASE REPORT

A 32-year-old Wa ethnic minority male (designated YN) with a 1-year history of abnormal gait and insecure balance from Yunnan province was diagnosed with HIV-1 infection in 2006. The patient had a previous diagnosis of tuberculous meningitis with confusion and fever as well as limb ataxias 2 years ago, which was cured with 1 year of anti-tubercle bacillus therapy combined with isoniazid, rifampicin, pyrazinamide and ethambutol. At that time, the patient started to receive continuous antiretroviral therapy including AZT, 3TC and EFV. The clinical data and laboratory test results showed that the HIV RNA viral load of the patient was <50 copies/ml and the CD4+ T cell count was 179 cells/mm³ at the time of admission. Brain MRI showed a hypodense lesion 6 mm in diameter, and contrast-enhancing focal brain lesion in the left Sylvian cistern. In CSF, total white blood cell count was 48 × 10⁶/l (75% neutrophils, 25% monocytes), protein was 2·0 g/l, glucose was 2·44 mmol/l and chloride was 112·0 mmol/l. HIV RNA viral load in CSF was 3560 copies/ml. CSF and culture staining for mycobacterial and bacterial tests were negative during Lyme, venereal disease research laboratory test and cryptococcal antigen detection, but fungal spores were detected in the CSF. This patient was primarily diagnosed as cerebral toxoplasmosis and fungal encephalitis. The detailed characteristics of this case are given in Table 1.

Table 1. Demographics and clinical characteristics of the case

<table>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>32</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
</tr>
<tr>
<td>Duration of HIV infection</td>
<td>Approximately 2 years from diagnosis of HIV</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Wa nationality</td>
</tr>
<tr>
<td>Transmission route</td>
<td>Intravenous drug use</td>
</tr>
<tr>
<td>HIV infection stage</td>
<td>CDC₃</td>
</tr>
<tr>
<td>Combined antiretroviral therapy</td>
<td>AZT, 3TC and EFV</td>
</tr>
<tr>
<td>CD4+ cell count on admission (cells/mm³)</td>
<td>179 (600–1000)</td>
</tr>
<tr>
<td>HIV-1 viral load on admission</td>
<td>In blood (copies/ml) &lt;50</td>
</tr>
<tr>
<td></td>
<td>In CSF (copies/ml) 3560</td>
</tr>
<tr>
<td>Neurological complications</td>
<td>Cerebral toxoplasmosis, fungal encephalitis</td>
</tr>
<tr>
<td>Laboratory test of CSF</td>
<td></td>
</tr>
<tr>
<td>Total white blood cell count</td>
<td>48 (0–8)</td>
</tr>
<tr>
<td>(×10⁶ cells/l)</td>
<td></td>
</tr>
<tr>
<td>Protein (g/l)</td>
<td>2·0 (0–0·4)</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>2·44 (2·5–4·5)</td>
</tr>
<tr>
<td>Chloride (mmol/l)</td>
<td>112·0 (120–132)</td>
</tr>
<tr>
<td>Fungal spores</td>
<td>+</td>
</tr>
<tr>
<td>Mycobacterial</td>
<td>–</td>
</tr>
<tr>
<td>Bacterial</td>
<td>–</td>
</tr>
</tbody>
</table>

Values given in parentheses are the normal range for the tests.

MATERIALS AND METHODS

Viral RNA was purified from CSF stored at −80 °C using the QIAamp Viral RNA kit (Qiagen, Germany) according to the manufacturer’s protocol. E2 and 5′-NCR genes were amplified and sequenced. Detailed experimental procedures were as follows: the purified RNA was subjected to RT–PCR amplification with 2·5 μg total RNA in 25 μl RT reaction mix at 37 °C for 50 min using random hexamers as the primers (SuperScript III First-Strand Synthesis System for RT–PCR, Invitrogen USA). The RT–PCR products were selected as the templates for the nested PCR (primers specific for E2 and 5′-NCR are given in Table 2). Multiple GBV-C negative controls were applied to detect any possible contaminations. PCR was performed in a 9600 Thermal Cycler (Applied Biosystems, USA) with a primer concentration of 400 nM and template concentration of 100 nM in the PCR reaction mix. RT–PCR parameters included pre-denaturation at
94 °C for 2 min and then 30 amplification cycles with denaturation at 94 °C for 15 s, annealing at 50 °C for 30 s and extension at 72 °C for 45 s, followed by a supplementary extension at 72 °C for 10 min. For the amplification of the 5'-NCR gene, the detailed experimental procedures were same as previously reported [21]. PCR products of E2 were cloned using the Ta cloning system (Takara, China), and randomly selected clones were sequenced on an ABI 3730 Genetic Analyzer (Applied Biosystems). The E2 sequences from each clone were aligned with reference sequences from different GBV-C genotypes available from GenBank (NCBI website) by the neighbour-joining sequence alignment program of Mega 5.0 software (mega.software.informer.com/5.0). The PCR product of 5'-NCR from the CSF was directly sequenced and aligned with reference sequences by the maximum composite likelihood model implemented in the Mega 5.0 software package.

Then, GBV-C viral load in the CSF was evaluated by quantitative real-time PCR (qPCR), using the same method as a previously published study [21]. Briefly, a standard curve of the GBV-C NCR plasmid was quantified using the universal qPCR method in a 25 μl reaction containing 1 × Taqman Universal PCR Master Mix (Applied Biosystems), 400 nM primer gbv-p1, 400 nM primer gbv-p2 and 200 nM fluoroscent probe gbv-probe (Invitrogen, China) (the primers and probe sequences are given in Table 2). Serial tenfold dilutions of GBV-C NCR plasmid were used to cover a range of $10^4$–$10^7$ molecules per reaction. The results indicated that GBV-C viral load was 6·5 log copies/ml in the CSF.

Furthermore, in order to test the incidence of GBV-C in the CSF of HIV/AIDS patients, the 5'-NCR and E2 genes of paired blood and CSF from five HIV-positive patients (designated BJ40, BJ42, BJ51, BJ76, BJ102) who were co-infected with GBV-C without the symptoms of opportunistic brain infection were amplified.

### RESULTS

Both 5'-NCR (233 bp product) and E2 (1242 bp product) genes were successfully amplified from the CSF of patient YN. Regarding the five patients (BJ40, BJ42, BJ51, BJ76, BJ102) without opportunistic CNS infection, both 5'-NCR and E2 genes were positive in the blood, but were absent from all paired CSF. The phylogenetic tree from the E2 region showed that all
of these sequences from six patients belonged to genotype 3, and the eight E2 clones from the CSF of patient YN clustered closely with references YXX1130 and JL2914 (Fig. 1). All nine sequences (one from the 5′-NCR clone and eight from E2 clones) from the CSF of patient YN generated in this study were deposited in GenBank with accession numbers KF234774–KF234782.

**DISCUSSION**

GBV-C is currently believed to be non-pathogenic to humans. Usually, the co-infection of GBV-C in HIV-infected patients is due to the similar transmission route [3, 13, 22]. It appears that GBV-C could slow the progression of HIV disease and improve patient’s outcome by a number of possible
mechanisms. In general, GBV-C co-infection is associated with the reduced activation of CD4+ and CD8+ T cells in both HIV viraemic and HIV RNA-suppressed patients [23]. Some viral protein products can inhibit HIV replication on CD4+ T lymphocytes in vitro [24–28]. Furthermore, GBV-C co-infection in HIV-1-infected patients can lead to the reduced expression of two major HIV-1 co-receptors such as CCR5 and CXCR4 in CD4+ T cells at an advanced stage of AIDS [29].

Previously, GBV-C has been detected in human lymphoid tissue, serum, muscle, spleen, liver and kidney, but not the brain [30, 31]. Recently, Kriesel et al. reported the concurrent occurrence of both GBV-C genomic RNA and negative-strand replication intermediates in brain tissue of a patient with multiple sclerosis, suggesting that it can be replicated in the CNS of the patient with multiple sclerosis at a very low occurrence rate [32]. However, the presence of GBV-C in the CNS of HIV-1-infected patients has not been reported until now. In the present study, a high GBV-C viral load was detected in the CSF of a HIV/AIDS case with an opportunistic brain infection. In order to detect the incidence of GBV-C in the CSF of HIV/AIDS patients, we tested CSF specimens from five cases of HIV/GBV-C co-infected patients who were free of opportunistic brain infection. However, we failed to detect GBV-C viraemia in any of those five CSF specimens, suggesting that the incidence of GBV-C in the CSF of HIV/AIDS patients is low. Similar results have been observed in HCV, another Flaviviridae virus that is known to be trophic for neural tissue [33, 34].

One of the possibilities for the presence of GBV-C virions in the CSF is that CSF samples are contaminated by blood at the time of lumbar puncture, but this is unlikely due to the absence of blood in CSF samples. The second possibility to explain the findings is the passive transferring of virions via the destroyed blood–brain barrier of patients with opportunistic CNS infection. This hypothesis is supported by the case with neurological complications (cerebral toxoplasmosis, fungal encephalitis) and the CSF from patients without opportunistic brain infection. The third possibility is that GBV-C is ‘passively’ introduced into the CSF by inflammatory white cell infiltrate. Moreover, the total white blood cell counts in the CSF of the five patients were in the normal range (0–8 × 10⁶/l), and far below the extent of patient YN (48 × 10⁶/l) based on medical records. This assumption seems reasonable. The last possibility is that the presence of GBV-C genomic RNA in the CSF samples of the HIV/AIDS patients may be associated with the productive infection in CNS, which is similar to HCV in the brain of HIV/AIDS patients [35]. However, due to lack of brain tissue, we were unable to determine whether or not GBV-C can replicate in brain tissue.

In addition, we were unable to collect paired blood samples from patient YN during his hospitalization. Therefore, we did not know if the GBV-C sequences in the blood samples were identical to the nucleic acid sequence in the CSF. Phylogenetic analysis based on the E2 region shows that little genomic diversity is observed in the nucleotides of E2 from the CSF; on average, there is only 0·3% sequence divergence in all eight E2 nucleotide sequences from each other corresponding to the 7·8% divergence to the reference genotype 3 strains including YXX1130, JL2914 andXA2044 that are isolated from Hebei province in northern China. To some extent, this means little immune pressure in the CSF of GBV-C virus from the host (Fig. 1).

In conclusion, in this study we have detected GBV-C genomic RNA, first in the CSF of the case with HIV/AIDS infection who had an opportunistic brain infection with cerebral toxoplasmosis and fungal encephalitis. Prior to our study, GBV-C was considered for testing only in the blood of the patients with HIV/AIDS co-infection. The high titre of GBV-C viral loads in the CSF reveals the possibility of passive transfer or the active production of GBV-C virions in CNS, although we were unable to detect the GBV-C replication intermediate strand due to the lack of brain tissue. Both hypotheses raise the possibility that the CNS may be another site for GBV-C replication and the destroyed integrity of the blood–brain barrier may play a key role in the invasion GBV-C into the brain. Despite this, the effect of co-infection of GBV-C in the brain of HIV-infected patients remains obscure. Further study on the neuropathological effect of co-infection by GBV-C on the CNS of HIV-infected patients should be conducted.

**ACKNOWLEDGEMENTS**

This work was supported by Hepatopathy & AIDS project of You An Hospital (Z. Liu, BJYAH-2011-062) and the Capital Health Development Research projects (Z. Liu, Capital Development 2011-1011-01), Beijing Key Laboratory for AIDS Research (W. Li, BZ0089), Beijing Natural Science Foundation (7142078 to
W. Li and 7132077 to D. Mou). Twelfth Key Science and Technology Five Year Plan of China (2012ZX10001-006 to H. Wu and 2012BAI15B08 to D. Chen) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (H. Wu, ZY201401).

DECLARATION OF INTEREST
None.

REFERENCES


